DekaBank Deutsche Girozentrale grew its stake in shares of Edwards Lifesciences Corp (NYSE:EW) by 0.5% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 62,669 shares of the medical research company’s stock after acquiring an additional 320 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Edwards Lifesciences were worth $11,728,000 at the end of the most recent reporting period.
Several other institutional investors also recently added to or reduced their stakes in EW. Jennison Associates LLC grew its position in shares of Edwards Lifesciences by 40.2% during the 1st quarter. Jennison Associates LLC now owns 5,763,824 shares of the medical research company’s stock valued at $1,102,792,000 after acquiring an additional 1,651,691 shares during the period. BlackRock Inc. grew its position in shares of Edwards Lifesciences by 4.7% during the 1st quarter. BlackRock Inc. now owns 17,211,498 shares of the medical research company’s stock valued at $3,293,075,000 after acquiring an additional 780,079 shares during the period. FMR LLC grew its position in shares of Edwards Lifesciences by 7.9% during the 1st quarter. FMR LLC now owns 8,175,796 shares of the medical research company’s stock valued at $1,564,274,000 after acquiring an additional 598,976 shares during the period. Bessemer Group Inc. grew its position in shares of Edwards Lifesciences by 56,300.0% during the 2nd quarter. Bessemer Group Inc. now owns 503,652 shares of the medical research company’s stock valued at $93,045,000 after acquiring an additional 502,759 shares during the period. Finally, Thoroughbred Financial Services LLC boosted its holdings in Edwards Lifesciences by 20,429.8% in the 2nd quarter. Thoroughbred Financial Services LLC now owns 267,503 shares of the medical research company’s stock worth $26,750,000 after buying an additional 266,200 shares during the period. 82.43% of the stock is owned by hedge funds and other institutional investors.
Shares of EW opened at $219.34 on Friday. The firm’s 50-day moving average price is $201.89 and its 200-day moving average price is $185.13. The firm has a market capitalization of $45.62 billion, a price-to-earnings ratio of 46.67, a PEG ratio of 2.69 and a beta of 0.87. The company has a current ratio of 3.38, a quick ratio of 2.48 and a debt-to-equity ratio of 0.18. Edwards Lifesciences Corp has a 1-year low of $136.44 and a 1-year high of $220.48.
Edwards Lifesciences (NYSE:EW) last announced its earnings results on Tuesday, July 23rd. The medical research company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.33 by $0.05. The firm had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.04 billion. Edwards Lifesciences had a net margin of 18.29% and a return on equity of 31.25%. The company’s revenue for the quarter was up 15.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.24 EPS. On average, research analysts forecast that Edwards Lifesciences Corp will post 5.34 EPS for the current fiscal year.
Several analysts have recently weighed in on the stock. Barclays raised their price objective on shares of Edwards Lifesciences from $160.00 to $175.00 and gave the company an “underweight” rating in a research report on Wednesday, July 24th. Deutsche Bank increased their target price on shares of Edwards Lifesciences from $164.00 to $184.00 and gave the company a “hold” rating in a report on Wednesday, April 24th. BMO Capital Markets increased their target price on shares of Edwards Lifesciences from $204.00 to $224.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Bank of America reaffirmed a “buy” rating and set a $225.00 target price (up previously from $215.00) on shares of Edwards Lifesciences in a report on Wednesday, July 24th. Finally, Zacks Investment Research raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $232.00 target price on the stock in a report on Thursday, July 25th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $204.74.
In related news, VP Donald E. Bobo, Jr. sold 3,000 shares of Edwards Lifesciences stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $169.60, for a total transaction of $508,800.00. Following the completion of the transaction, the vice president now directly owns 20,674 shares of the company’s stock, valued at approximately $3,506,310.40. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Michael A. Mussallem sold 22,850 shares of Edwards Lifesciences stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $184.27, for a total transaction of $4,210,569.50. Following the transaction, the chief executive officer now directly owns 95,770 shares of the company’s stock, valued at $17,647,537.90. The disclosure for this sale can be found here. Insiders have sold a total of 137,951 shares of company stock worth $27,076,240 in the last ninety days. Insiders own 1.63% of the company’s stock.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Read More: How do analysts define an oversold condition?
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.